NCT06619483View on ClinicalTrials.gov

A Study to Learn How Safe BAY3018250 is, How it Moves Into, Through and Out of the Body, and How it Affects the Body in Healthy Chinese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 10, 2024

Primary Completion Date

January 24, 2025

Study Completion Date

January 24, 2025

Conditions
Acute Venous and Arterial Thrombotic and Thromboembolic EventsHealthy Volunteers
Interventions
DRUG

BAY3018250 Dose 1

Single dose

DRUG

Placebo

Matching placebo to BAY3018250

DRUG

BAY3018250 Dose 2

Single dose

Trial Locations (1)

510405

The First Affiliated Hospital of Guangzhou University of TCM, Guangzhou

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT06619483 - A Study to Learn How Safe BAY3018250 is, How it Moves Into, Through and Out of the Body, and How it Affects the Body in Healthy Chinese Participants | Biotech Hunter | Biotech Hunter